Abstract:Abstract Background Monoclonal antibodies (mAb) comprise of two Fab fragments and one Fc fragment or one F(ab)’2 fragment and one Fc fragment. While a full-length mAb is frequently used as an assay reagent for bioanalysis, mAb fragments are required in certain cases. For example, to build a sandwich assay for detection of anti-drug antibodies (ADA) for therapeutic antibodies, Fab or F(ab)’2 fragment is used instead of a full-length mAb as capture reagent. This is because therapeutic antibodies, either humanized or fully human, are in many ways indistinguishable from the ADA generated in patients, especially in Fc fragment. When ADA detection methods utilizes anti-human Fc antibodies as the detection reagent, the full-length mAb drug will be directly bound by the detection reagent, causing interference. Preparation of a Fab or F(ab)’2 fragment is therefore needed. Methods and results We are developing a method for enzymatic digestion of therapeutic antibodies to generate monovalent Fab or bivalent F(ab’)2 fragments in this study. With such reagents becoming available, a sandwich ADA assay formats can be expanded to allow anti-human Fc antibodies as detection regents. To standardize the method, we explored various enzymatic conditions, including type of enzymes (i.e., pepsin, papain, and IdeS Protease), digestion-time (1, 2, 4, and 6 h), enzyme to antibody ratio (1:10, 1:20, and 1:40 w/w), IgG species and isotypes (human IgG1-κ, IgG1-λ, and IgG4-κ). The enzymatic hydrolysates were quantified by NanoDrop and purified by dialysis (10K MWCO) and Protein A/G/L magnetic bead methods. The effective recovery of truncated antibodies was > 90%, as assessed by reduced/non-reduced SDS-PAGE and ELISA analysis. Digestion of human IgG1 and IgG4 with pepsin resulted into a complete cleavage into F(ab')2 fragments and degradation of Fc fragments. While IdeS Protease produced an equivalent quantity of F(ab’)2 and Fc fragments with a similar efficiency, removal of the intact Fc fragment was required as an additional step. If the Fab fragments were desired, papain could be used with yield being over 90%. We have subsequently utilized either Fab or F(ab’)2 as a capture reagent for ADA detection. Conclusion We have successfully developed the enzymatic digestion method to prepare Fab or F(ab’)2 fragments. The optimized conditions described here are broadly applicable to different IgG isotypes across many therapeutic antibodies.

Preparation and identification of the F(ab)2 fragment of rabbit's polyclonal antibodies against human ouabain

Preparation and identification of the fragment of rabbit's polyclonal antibodies against human ouabain

Preparation and separation of Fab and Fc fragments from human immunoglobulin G with papain digestion

Development of a Hybrid Biomimetic Ligand with High Selectivity and Mild Elution for Antibody Purification

[Preparation and Application of Anti-Ouabain IgY Antibody].

Preparation of anti-ouabain IgY in hen egg yolk

DEVELOPMENT OF A METHOD FOR PRODUCING FAB/F(AB’)2 FRAGMENTS FROM A FULL-LENGTH MONOCLONAL ANTIBODY FOR BIOANALYTICAL ASSAYS

Preparation and Identification of Fab' Fragments from Chicken Egg Yolk Immunoglobulin Y

[Comparison Between Anti-Ouabain Egg Yolk(igy) and Rabbit Antibody(igg) in Enzyme-Linked Immunosorbent Assay].

Preparation and Identification of the Rabbit Anti-human Immune-related Gene Guanosine Triphosphate Polyclonal Antibody

High-Level Expression, Purification, Polyclonal Antibody Preparation Against Recombinant Oprd from Pseudomonas Aeruginosa

Preparation and Characterization of Polyclonal Antibodies Against Rat Sodium Pump Alpha 2 Subunit M1-M2 Extra Membrane Fragment

Preparation and Application of Polyclonal Antibody Against 4-Methylphenol

PREPARATION OF FUMONISIN B_1 ARTIFICIAL ANTIGEN AND MOUSE POLYCLONAL ANTISERUM

Preparation of Phytase Mouse Polyclonal Antiserum

Immobilization of Protein A and Its Application in Antibody Affinity Purification

Preparation and Analysis of Polycolonal Antibody Against ANGPTL 2 Fibrinogen Like Domain

Preparation and Purification of Antibody Against Pemphigus Vulgaris Antigen

[Preparation of Monoclonal Antibody Against 4-Amylphenol and Homology Modeling of Its Fv Fragment].

Preparation of Anti-LeERF2 Polyclonal Antibody

[Recombinant Expression of Human Fibrogenic Factors and Preparation of Polyclonal Antibodies].